BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will…
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will…
Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia and Xgeva, respectively. The approval covers Bosaya in a 60mg/ml…
Eli Lilly has agreed to acquire Massachusetts-based gene therapy developer, Kelonia Therapeutics, for up to $7bn – marking the pharma’s second foray into the in vivo space this year. Through…
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their supplemental biologics licence application (sBLA) for perioperative Padcev (enfortumab vedotin-ejfv) combined with…
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company. The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of…
A survey by digital healthcare provider Zava has revealed that British patients are increasingly turning to potentially unregulated weight loss drugs as demand surges and global medicine prices climb. Of…
Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest move to drive improved patient outcomes through the technologies’ application.…